
Tesamorelin is a stabilised GHRH analog studied for its effect on endogenous growth hormone release and visceral adipose tissue. Supplied lyophilized, preservative free, and verified by third-party LC-MS.
| Purity | ≥99% (LC-MS verified) |
| Form | Lyophilized powder, preservative free |
| Storage | Cool and dry; refrigerate after reconstitution |
| Batch | COA available on request |
Tesamorelin is a stabilised GHRH analog studied for its effect on endogenous growth hormone release and visceral adipose tissue. Supplied lyophilized, preservative free, and verified by third-party LC-MS.
Tesamorelin is a stabilised analogue of growth hormone-releasing hormone (GHRH). A trans-3-hexenoyl group attached to the N-terminus protects it from rapid enzymatic degradation, giving it a longer active window than native GHRH while preserving receptor binding.
Because it acts upstream — stimulating the pituitary to release its own growth hormone rather than supplying growth hormone directly — it is studied as a secretagogue, and the resulting release follows the body's own pulsatile pattern.
Supplied as lyophilized powder for laboratory research, verified per lot. Not for human consumption.
Tesamorelin binds pituitary GHRH receptors, stimulating endogenous growth hormone release. The distinction from exogenous growth hormone administration is that feedback regulation via somatostatin remains intact.
The most substantial clinical literature concerns visceral adipose tissue measured by CT imaging, examined in populations with HIV-associated lipodystrophy. This is the indication for which it received approval.
A related strand examines liver fat content and enzyme markers alongside visceral fat reduction, addressing whether the two move together.
Studies routinely track insulin-like growth factor 1 as the measurable downstream consequence of growth hormone release, since IGF-1 has a longer half-life and is easier to assay than pulsatile GH itself.
Tesamorelin is approved as a finished pharmaceutical for a specific indication in some jurisdictions. Research-grade material is not a finished pharmaceutical.
Concentration is set by the volume of diluent added. For a 10mg vial, 2mL of bacteriostatic water yields 5mg/mL. Calculate the working concentration your protocol requires rather than following a generic figure.
| State | Temperature | Practical shelf life |
|---|---|---|
| Lyophilized, sealed | −20 °C | 24+ months |
| Lyophilized, sealed | 2–8 °C | ~12 months |
| Lyophilized, sealed | Room temperature | Weeks — transit only |
| Reconstituted, bacteriostatic water | 2–8 °C | ~3–4 weeks |
| Reconstituted, sterile water | 2–8 °C | Same session |
Lyophilized peptide is stable enough to survive shipping at ambient temperature, which is why cold-chain courier service is not required for transit. Long-term storage is a different matter — material intended to be held for months belongs in a freezer.
Protect from light, and avoid repeated freeze-thaw cycles. Each cycle causes measurable degradation, so dividing a reconstituted stock into single-use aliquots before freezing is preferable to thawing and refreezing one vial repeatedly.
Every lot is tested by an independent laboratory using two orthogonal methods. HPLC (high-performance liquid chromatography) establishes purity as a percentage of total peptide content, separating the target compound from truncated sequences and synthesis by-products. LC-MS (liquid chromatography–mass spectrometry) confirms molecular identity by mass.
Both matter. Purity alone is insufficient — a 99% pure sample of the wrong compound is still the wrong compound. Together the two tests establish identity and quality, which is why Tesamorelin is released only after both pass.
The certificate of analysis references the lot number printed on your vial label. Request the COA for your lot at [email protected].
Peer-reviewed studies indexed in PubMed. Each links to the abstract and, where a free copy exists, to the full text. We link primary sources rather than summarising them second-hand.
Compounds studied alongside this one, or acting through related pathways.
Join the Peps Depot mailing list for high-demand restock alerts, subscriber-only offers, release updates and priority access — plus The Friday Brief, our weekly peptide research newsletter covering what actually moved that week. New compounds, new trial data, regulatory shifts.